|本期目录/Table of Contents|

[1]刘 豫,薄志强,张志宏.糖尿病及二甲双胍对上尿路肿瘤术后复发的影响[J].天津医科大学学报,2017,23(01):53-55.
　LIU Yu,BO Zhi-qiang,ZHANG Zhi-hong.Effect of diabetes mellitus and metformin on intravesical recurrence after radical operation in patients with upper urinary tract urothelial carcinoma[J].Journal of Tianjin Medical University,2017,23(01):53-55.
点击复制

糖尿病及二甲双胍对上尿路肿瘤术后复发的影响(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
23卷
期数:
2017年01期
页码:
53-55
栏目:
临床医学
出版日期:
2017-01-16

文章信息/Info

Title:
Effect of diabetes mellitus and metformin on intravesical recurrence after radical operation in patients with upper urinary tract urothelial carcinoma
文章编号:
1006-8147（2017）01-0053-03
作者:
刘 豫; 薄志强; 张志宏
(天津医科大学第二医院泌尿外科,天津市泌尿外科研究所,天津 300211)
Author(s):
LIU Yu;  BO Zhi-qiang;  ZHANG Zhi-hong
(Department of Urology, The Second Hospital ,Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China)
关键词:
糖尿病; 二甲双胍; 尿路上皮癌; 根治性肾输尿管切除术; 膀胱肿瘤; 膀胱内复发
Keywords:
diabetes mellitus' target="_blank" rel="external">">diabetes mellitus;  metformin;  upper urinary tract urothelial carcinoma;  radical nephroureterectomies;  bladder neoplasm;  intravesical recurrence
分类号:
R737
DOI:
-
文献标志码:
A
摘要:
目的 ：探究糖尿病(DM)及二甲双胍的使用对上尿路肿瘤(UUT-UC)患者行根治性肾输尿管切除(RNU)术后膀胱内肿瘤复发的影响。方法：收集 行RNU术且既往无膀胱肿瘤病史的301例UUT-UC患者临床资料。应用Kaplan-Meier法绘制生存曲线，Cox回归模型探讨RNU术后膀胱内肿瘤复发的临床影响因素。结果：纳入研究的患者中有68例(22.6%)有DM，其中36例(12.0%)使用二甲双胍降糖药，随访期间有82例(27.2%)出现膀胱内肿瘤复发。非DM、DM未使用二甲双胍及DM使用二甲双胍患者膀胱内肿瘤复发的发生率分别为25.3%、53.1%、16.7%。Cox回归模型多因素分析显示，与非DM及DM使用二甲双胍相比，DM未使用二甲双胍患者无复发生存期(RFS)显著缩短(分别P=0.004；P=0.007)，而DM使用二甲双胍较非DM患者的RFS差异无统计学意义(P=0.298)。结论：DM未使用二甲双胍是UUT-UC患者术后膀胱内肿瘤复发的危险因素，而使用二甲双胍可以降低甚至消除这种不利影响。
Abstract:
?Objective: To assess the effect of diabetes mellitus (DM) and metformin on intravesical recurrence of patients treated with radical nephroureterectomies (RNU) for upper urinary tract urothelial carcinoma (UUT-UC). Methods: The clinicopathological data of 301 patients with UUT-UC who received RNU and had no histories of bladder neoplasm previously were retrospectively analyzed. Kaplan-Meier survival curves were applied to estimate survival time and Cox’s regression model was conducted to explore the clinical impact factors for intravesical recurrence after RNU. Results: Of the 301 patients, a total of 68 (22.6%) patients had DM, of which 36 (12.0%) patients used metformin, and 82 (27.2%) patients experienced intravesical recurrences. Intravesical recurrences were discovered in 25.3%, 53.1% and 16.7% of non-diabetic patients, DM without metformin, and DM with metformin, respectively. In Cox’s regression model multivariate analysis, diabetic patients who did not use metformin had a significantly shorter duration of recurrence-free survival (RFS), compared with non-diabetic patients and diabetic patients who used metformin (P=0.004, P=0.007 respectively), but diabetic patients who used metformin did not have a higher risk of RFS than non-diabetic patients (P=0.298). Conclusion: DM patients with UUT-UC not taking metformin may be at an increased risk of intravesical recurrence after RNU, but the use of metformin can reduce or even eliminate the poor prognosis.

参考文献/References:

[1] Xylinas E, Colin P, Audenet F, et al. Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study [J]. World J Urol, 2013, 31(1): 61
[2] Novara G, De Marco V, Dalpiaz O, et al. Independent predictors of metachronous bladder transitional cell carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract [J]. BJU Int, 2008, 101(11): 1368
[3] Brown J S, Wessells H, Chancellor M B, et al. Urologic complications of diabetes [J]. Diabetes Care, 2005, 28(1): 177
[4] Evans J M, Donnelly L A, Emslie-Smith A M, et al. Metformin and reduced risk of cancer in diabetic patients [J]. BMJ, 2005, 330(7503): 1304
[5] Landman G W, Kleefstra N, van Hateren K J, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16 [J]. Diabetes Care, 2010, 33(2): 322
[6] Tseng C H, Chong C K, Tseng C P, et al. Age-related risk of mortality from bladder cancer in diabetic patients: a 12-year follow-up of a national cohort in Taiwan [J]. Ann Med, 2009, 41(5): 371
[7] Fang H, Yao B, Yan Y, et al. Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis of observational studies [J]. Diabetes Technol Ther, 2013, 15(11): 914
[8] Hwang E C, Kim Y J, Hwang I S, et al. Impact of diabetes mellitus on recurrence and progression in patients with non-muscle invasive bladder carcinoma: a retrospective cohort study [J]. Int J Urol, 2011, 18(11): 769
[9] Liu S, Li Y, Lin T, et al. High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt [J]. Diabetes Res Clin Pract, 2011, 91(2): 177
[10] Metalli D, Lovat F, Tripodi F, et al. The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin [J]. Am J Pathol, 2010, 176(6): 2997
[11] Colmers I N, Bowker S L, Majumdar S R, et al. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis [J]. CMAJ, 2012, 184(12): E675
[12] Witters L A. The blooming of the French lilac [J]. J Clin Invest, 2001, 108(8): 1105
[13] Artola Menéndez S. Panorama of currently available treatments for patients with type 2 diabetes [J]. The ADA/EASD treatment algorithm. Safety and tolerability. Aten Primaria, 2010, 42 Suppl 1: 24
[14] Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action [J]. J Clin Invest, 2001, 108(8): 1167
[15] Boyle J G, Salt I P, McKay G A. Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic
target [J]. Diabet Med, 2010, 27(10): 1097
[16] Rattan R, Graham R P, Maguire J L, et al. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo [J]. Neoplasia, 2011, 13(5): 483
[17] Gotlieb W H, Saumet J, Beauchamp M C, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer [J]. Gynecol Oncol, 2008, 110(2): 246
[18] Spratt D E, Zhang C, Zumsteg Z S, et al. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality [J]. Eur Urol, 2013, 63(4): 709
[19] Rieken M, Xylinas E, Kluth L, et al. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma [J]. Urol Oncol, 2014, 32(1): 49.e7
[20] Rieken M, Xylinas E, Kluth L, et al. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer [J]. BJU Int, 2013, 112(8): 1105
[21] Jalving M, Gietema J A, Lefrandt J D, et al. Metformin: taking away the candy for cancer [J]. Eur J Cancer, 2010, 46(13): 2369

相似文献/References:

[1]王树峰,杨 丽,刘 寅.脂蛋白相关磷脂酶A2与冠心病和2型糖尿病的关系[J].天津医科大学学报,2013,19(06):456.
　WANG Shu-feng,YANG Li,LIU Yin.Relationship between lipoprotein-associated phospholipase A2 and coronary heart disease as well as type 2 diabetes mellitus[J].Journal of Tianjin Medical University,2013,19(01):456.
[2]苏东峰,聂秀玲,孙丽荣.2型糖尿病合并高尿酸血症临床特征及相关危险因素分析[J].天津医科大学学报,2013,19(06):481.
[3]武 鑫,李明珍,孙丽荣.2型糖尿病患者血清γ-谷氨酰转移酶与胰岛β细胞功能的关系[J].天津医科大学学报,2014,20(02):147.
　WU Xin,LI Ming-zhen,SUN Li-rong.Association of serum gamma-glutamyltransferase with islet β cell function in type 2 diabetic patients[J].Journal of Tianjin Medical University,2014,20(01):147.
[4]刘 芳,李明珍,孙丽荣.住院2型糖尿病患者睡眠质量与血糖及并发症的关系[J].天津医科大学学报,2014,20(03):213.
　LIU Fang,LI Ming-zhen,SUN Li-rong.Relationship between sleep quality and glucose level as well as diabetic complications in hospital patients with type 2 diabetes mellitus[J].Journal of Tianjin Medical University,2014,20(01):213.
[5]李凤英,朱铁虹.中年男性2型糖尿病患者促甲状腺激素与尿钙/肌酐比值的相关性研究[J].天津医科大学学报,2014,20(05):389.
　LI Feng-ying,ZHU Tie-hong.Relationship between thyroid stimulating hormone and urinary calcium/creatinine excretion in middle-aged man with type 2 diabetes[J].Journal of Tianjin Medical University,2014,20(01):389.
[6]谭艳萍,吴校伟,刘 寅,等. 冠心病合并糖尿病患者药物涂层支架术后观察[J].天津医科大学学报,2014,20(05):414.
[7]陈河清,郭秀梅,金力里.2型糖尿病患者牙周病与糖尿病肾病的相关性分析[J].天津医科大学学报,2014,20(06):469.
　CHEN He-qing,GUO Xiu-mei,JIN Li-li. Correlation between diabetic nephropathy and periodontal disease[J].Journal of Tianjin Medical University,2014,20(01):469.
[8]马 静,赵立华,谢 云.血浆纤维蛋白原与糖尿病肾病的相关性研究[J].天津医科大学学报,2015,21(03):60.
　Ma Jing,ZHAO Li-hua,XIE Yun.Relationship between plasma fibrinogen concentration and diabetic nephropathy [J].Journal of Tianjin Medical University,2015,21(01):60.
[9]马 静,赵立华,谢 云. 血浆纤维蛋白原与糖尿病肾病的相关性研究[J].天津医科大学学报,2015,21(01):60.
　MA Jing,ZHAO Li-hua,XIE Yun.Relationship between plasma fibrinogen concentration and diabetic nephropathy[J].Journal of Tianjin Medical University,2015,21(01):60.
[10]李 冰,冯 凭.罗格列酮干预糖尿病大鼠脂肪组织CMKLR1及Chemerin基因表达[J].天津医科大学学报,2015,21(06):484.
　LI Bing,FENG Ping.Effect of rosiglitazone on the expression of CMKLR1 and Chemerin mRNA in the adipose tissue of diabetic rat[J].Journal of Tianjin Medical University,2015,21(01):484.

备注/Memo

备注/Memo:
作者简介 刘豫(1990-)，男，硕士在读，研究方向：泌尿外科；通信作者：张志宏，E-mail: drzhangzhihong@163.com。
更新日期/Last Update: 2017-01-16